All Articles

Now debt-free with $14M in cash, Castellum is leveraging major Navy contracts to fuel its next phase of expansion through acquisitions and innovation.

Fortrea splits key roles, dedicating its CMO to scientific strategy and hiring a new president for clinical pharmacology in a bold post-spin-off move.

Cyclerion's novel therapy for treatment-resistant depression, using EEG-guided anesthesia, gains key FDA support and a top-tier advisory board.

Warner Bros. Discovery pushes for a Netflix merger but opens a one-week window for Paramount Skydance to fix its flawed bid. A bidding war looms.

Backed by Bessemer Investors, Tencarva Machinery continues its strategic expansion, acquiring a niche expert to solidify its dominance in the Ohio Valley.

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.

With all regulatory hurdles cleared, GDI makes a final push for shareholder approval on a $36.60 per share buyout from private equity firm Birch Hill.

How did a Tennessee 3PL achieve 18x shipment growth? A deep dive into the unified tech platform and AI strategy that’s rewriting the rules of freight.

With a massive dataset from $6.2B in prior authorizations, SamaCare's AI is speeding up access to critical drugs, but raises questions about market power.

The world's largest bedding company raises its dividend for the sixth time in five years, flexing financial muscle despite mixed signals from Wall Street.

Bausch Health heads to a key finance conference to address investor concerns over its massive debt, upcoming patent cliffs, and future strategic direction.

Brunswick Exploration launches a new drill program at a major Quebec lithium find, part of a global strategy in a surging market for critical minerals.

Citing 'prolonged underperformance,' activist investor Starboard Value seeks to replace Tripadvisor's board, igniting a battle for control.

Despite a $70M net loss and falling sales, chemical firm Orion S.A. highlights positive free cash flow and a new focus on financial discipline.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

Zefiro Methane founder accuses the board of entrenchment tactics, setting the stage for a critical BCSC hearing that will shape the company's future.

A new therapy for a rare brain cancer is one step closer to patients after the FDA accepted tirabrutinib for accelerated review, offering hope where few options exist.

A strategic merger creates a new aerospace and defense giant, but existing shareholders face significant dilution in a deal laden with both promise and risk.

Two small businesses from Pennsylvania are finding massive success in Asia, leveraging Coupang's AI-powered platform to bypass traditional export hurdles.

As global leaders gather in Mumbai, the focus shifts from climate negotiation to concrete action, testing new tools to accelerate progress toward COP31.